Trial evaluates maternal vaccine to protect newborns from Group B Streptococcus
A phase 1/2 clinical trial has demonstrated that Pfizer's investigational maternal vaccine for Group B Streptococcus is safe and effective at transferring antibodies to newborns. The study, led by Wits VIDA, highlights the potential to reduce neonatal sepsis and mortality.
Why it matters
This vaccine could significantly reduce infant mortality rates globally, particularly in low- and middle-income countries where GBS infections are most prevalent.
edited by Lisa Lock , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: CC0 Public Domain Researchers from the Wits Vaccines and Infectious Diseases Analytics (Wits VIDA) Research Unit at the University of the Witwatersrand (Wits) have played a leading role in an international phase 1/2 clinical trial demonstrating the safety and immunogenicity of an investigational maternal vaccine against Group B Streptococcus (GBS)—a major cause of life-threatening infections in newborns worldwide. The findings have been published in Nature Medicine .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in